Pancreatic Cancer Research

ResearcherWuhan Union HospitalNo recent work listed

Shichang Deng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5034650812. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2013: 5 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 1 paper

Papers 14

  1. Nutrient Stress-Dysregulated Antisense lncRNA GLS-AS Impairs GLS-Mediated Metabolism and Represses Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-0419↗
  2. MiRNA-646-mediated reciprocal repression between HIF-1α and MIIP contributes to tumorigenesis of pancreatic cancer. Co-author DOI 10.1038/s41388-017-0082-2↗
  3. Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription. Co-author DOI 10.1038/s41388-018-0382-1↗
  4. The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose. First author DOI 10.1038/s41419-017-0158-5↗
  5. ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca2+/RhoA pathway. Co-author DOI 10.1038/cddis.2017.189↗
  6. MiR-548an, Transcriptionally Downregulated by HIF1α/HDAC1, Suppresses Tumorigenesis of Pancreatic Cancer by Targeting Vimentin Expression. Co-author DOI 10.1158/1535-7163.mct-15-0877↗
  7. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. Co-author DOI 10.18632/oncotarget.6830↗
  8. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Co-author DOI 10.18632/oncotarget.5350↗
  9. Chronic pancreatitis and pancreatic cancer demonstrate active epithelial-mesenchymal transition profile, regulated by miR-217-SIRT1 pathway. Co-author DOI 10.1016/j.canlet.2014.08.007↗
  10. Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways. Co-author DOI 10.1016/j.pan.2013.01.001↗
  11. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKα1. Co-author DOI 10.1158/1535-7163.mct-12-0534-t↗
  12. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Co-author DOI 10.1158/1535-7163.mct-13-0296↗
  13. Hypermethylation of HIC1 promoter and aberrant expression of HIC1/SIRT1 might contribute to the carcinogenesis of pancreatic cancer. Co-author DOI 10.1245/s10434-012-2364-9↗
  14. MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. Co-author DOI 10.1371/journal.pone.0073803↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Zhao · 14 shared papers, 2013–2019 · strength 0.70
  2. Chunyou Wang · 14 shared papers, 2013–2019 · strength 0.70
  3. Shuai Zhu · 9 shared papers, 2013–2019 · strength 0.50
  4. Shi-Jiang Deng · 8 shared papers, 2014–2019 · strength 0.49
  5. Xiang Li · 9 shared papers, 2013–2018 · strength 0.44
  6. Mingliang Liu · 5 shared papers, 2016–2019 · strength 0.34
  7. Yan Jin · 5 shared papers, 2014–2018 · strength 0.29
  8. Qi Qin · 7 shared papers, 2013–2018 · strength 0.28
  9. Zhu Zeng · 4 shared papers, 2016–2019 · strength 0.27
  10. Ye Zeng · 3 shared papers, 2018–2019 · strength 0.22
  11. Jungang Zhang · 5 shared papers, 2013 · strength 0.17
  12. Fengyu Xu · 2 shared papers, 2018–2019 · strength 0.15
  13. Qiang Li · 2 shared papers, 2018–2019 · strength 0.15
  14. Yi Niu · 2 shared papers, 2013–2018 · strength 0.10
  15. Shuai Zhu · 2 shared papers, 2015–2016 · strength 0.09
  16. Tao Yin · 2 shared papers, 2014–2015 · strength 0.08
  17. Yang Liu · 1 shared paper, 2016 · strength 0.05
  18. Ming Yang · 1 shared paper, 2014 · strength 0.03
  19. Heshui Wu · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.